GSK (NYSE: GSK)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
GSK Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
GSK Company Info
The Company is a global healthcare group which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter medicines and health-related consumer products.
News & Analysis
A wave of litigation is coming into view.
Investors may be warming to the company's spin-off of its consumer healthcare division.
These 10 women CEOs are showing the value of leadership diversity.
GSK leads the race to deliver a vaccine for an untreated infectious disease.
The British drugmaker recently announced that it agreed to acquire a late-stage biopharmaceutical company.
Its late-stage pipeline is heavily weighted toward pandemic treatments.
GlaxoSmithKline's anemia of chronic kidney disease drug could be just months away from authorization in the European Union.
Looking for a healthcare stock with strong leadership? Our roundtable likes Immunocore, Axsome Therapeutics, and GlaxoSmithKline.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 01/29/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Podcast Episodes
A look at the complicated and emotionally fraught world of pharmaceutical drug marketing.
Digesting how the U.K. decision to exit the EU could affect healthcare stocks here and abroad.
GlaxoSmithKline takes on Pfizer, and Biogen battles Celgene in this healthcare edition of Industry Focus.
Earnings Transcripts
GSK earnings call for the period ending September 30, 2021.
GSK earnings call for the period ending June 30, 2021.
GSK earnings call for the period ending March 31, 2021.
GSK earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.